✦ LIBER ✦

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

✍ Scribed by Jean-Yves Pierga; Thierry Petit; Thierry Delozier; Jean-Marc Ferrero; Mario Campone; Joseph Gligorov; Florence Lerebours; Henri Roché; Thomas Bachelot; Emmanuelle Charafe-Jauffret; Maria Pavlyuk; Sandrine Kraemer; François-Clément Bidard; Patrice Viens

Book ID: 117785970
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 188 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70049-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Study of Primary Sys

Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer

✍ Seigo Nakamura; Masashi Ando; Norikazu Masuda; Kenjiro Aogi; Hiroyo Ino; Hiroji 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 401 KB

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB

2129 POSTER An open-label study of capec

2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

✍ D. Tripathy; C. Moisa; S. Glück 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Adjuvant docetaxel and cyclophosphamide

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

✍ Jones, Stephen E; Collea, Rufus; Paul, Devchand; Sedlacek, Scot; Favret, Anne M; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 210 KB

Phase 2, Multicenter, Single-Arm Study o

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

✍ Wilks, Sharon; Puhalla, Shannon; O'Shaughnessy, Joyce; Schwartzberg, Lee; Berrak 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 169 KB

Preference for subcutaneous or intraveno

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

✍ Pivot, Xavier; Gligorov, Joseph; Müller, Volkmar; Barrett-Lee, Peter; Verma, Sun 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 213 KB